Supreme Court Backs Lisa Cook, Defends Federal Reserve Independence Against Trump Firing Attempt 
DOE Declares Power Grid Emergency as Extreme Heat Strains PJM Electricity Supply 
Why the future of marijuana legalization remains hazy despite high public support 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
U.S. Military Expands Venezuela Earthquake Relief Mission as Troop Presence Tops 900 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Trump Reports $1.4 Billion in Crypto Income as Digital Assets Become Top Wealth Source 
Trump Prioritizes Iran Diplomacy Over Military Action as Nuclear Talks Continue 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
Maria Corina Machado Vows Return to Venezuela After Earthquakes Despite Obstacles 
Trump Administration Declines USMCA Renewal, Opens Talks on New Trade Changes 
Trump Suspends Some Morocco Fertilizer Tariffs to Ease U.S. Supply Shortage 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) is facing leadership uncertainty after acting director Jeffery Taubenberger stepped down during ongoing Ebola and hantavirus outbreak concerns. The departure was revealed Thursday during a Senate hearing on the National Institutes of Health (NIH) 2027 budget, sparking criticism from Democratic lawmakers over the agency’s preparedness for emerging infectious diseases.
Taubenberger assumed the acting director role in April 2025 after the Trump administration removed former NIAID leadership. Senator Tammy Baldwin announced his resignation at the hearing, while Senator Patty Murray also referenced the sudden exit. NIH Director Jay Bhattacharya did not deny the reports and said the agency is shifting priorities away from civilian biodefense and pandemic preparedness toward direct infectious disease response, allergy research, and immunology.
The leadership change comes as global health officials monitor an Ebola outbreak in the Democratic Republic of Congo and potential hantavirus exposure linked to a luxury cruise ship outbreak in the Atlantic Ocean. Although no confirmed U.S. cases of Andes hantavirus have been reported, 41 individuals, including 18 people quarantined in Nebraska, remain under observation.
Former NIAID director Jeanne Marrazzo criticized the current situation, warning that the institute appears disconnected from researchers and pharmaceutical companies working on Ebola treatments. Under former director Anthony Fauci, NIAID played a major role in managing both the COVID-19 pandemic and the 2014-2016 Ebola crisis in West Africa.
The latest departures add to growing concerns about instability within the NIH, where more than half of its 27 institutes are currently overseen by acting directors. NIAID, the NIH’s second-largest institute with a budget exceeding $6.5 billion, remains central to U.S. infectious disease research and public health response efforts.
